TEVA PHARMACEUTICAL INDUSTRIES LIMITED Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVA) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$295.00 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-05.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2025-02-05
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was -$295.00M.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2023 was -$144.00M.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2022 was -$727.00M, a 581.46% decline from fiscal 2021.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2021 was $151.00M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month as first filed |
|---|---|---|
| 2024-12-31 | -$295.00M 10-K · filed 2025-02-05 | |
| 2023-12-31 | -$144.00M 10-K · filed 2025-02-05 | |
| 2022-12-31 | -$727.00M 10-K · filed 2025-02-05 | -$705.00M 10-K · filed 2023-02-10 |
| 2021-12-31 | $151.00M 10-K · filed 2024-02-12 | |
| 2020-12-31 | -$1.01B 10-K · filed 2023-02-10 | |
| 2019-12-31 | -$291.00M 10-K · filed 2022-02-09 | |
| 2018-12-31 | -$597.00M 10-K · filed 2021-02-10 | |
| 2017-12-31 | -$4.41B 10-K · filed 2020-02-21 | |
| 2016-12-31 | $206.00M 10-K · filed 2019-02-19 | |
| 2015-12-31 | $623.00M 10-K · filed 2018-02-12 | |
| 2014-12-31 | $964.00M 20-F · filed 2017-02-15 | |
| 2013-12-31 | $313.00M 20-F · filed 2016-02-11 | |
| 2012-12-31 | $455.00M 20-F · filed 2015-02-09 | |
| 2011-12-31 | $709.00M 20-F · filed 2014-02-10 |